We are pleased to welcome ExoNostic to the Innovation Gateway, strengthening our growing community of pioneering life-science companies at the London Cancer District.
ExoNostic is developing next-generation liquid biopsy diagnostics that enable earlier and more accessible disease detection. Their platform applies holistic molecular analysis to small biological samples, generating detailed diagnostic insights that support early cancer detection, treatment monitoring and wider biomarker discovery.
By joining the Innovation Gateway, ExoNostic will benefit from state-of-the-art laboratory and office facilities, as well as opportunities to collaborate with world-leading scientists and clinicians across The Institute of Cancer Research.
Space remains available for organisations looking to accelerate innovation in oncology and related fields.
